Adicet Bio, Inc. Business Acquisition, Pro Forma Net Income (Loss)
Adicet Bio, Inc. (ACET) reported Business Acquisition, Pro Forma Net Income (Loss) of -$35.76 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2021-03-12
- Adicet Bio, Inc. business acquisition, pro forma net income (loss) for fiscal 2020 was -$35.76M.
- Adicet Bio, Inc. business acquisition, pro forma net income (loss) for fiscal 2019 was -$113.15M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|
| 2020-12-31 | -$35.76M 10-K · filed 2021-03-12 |
| 2019-12-31 | -$113.15M 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |